- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Patent holdings for IPC class C07D 261/18
Total number of patents in this class: 320
10-year publication summary
26
|
36
|
33
|
20
|
27
|
28
|
21
|
11
|
21
|
5
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Theravance Biopharma R&D IP, LLC | 460 |
48 |
Proteostasis Therapeutics, Inc. | 70 |
9 |
F. Hoffmann-La Roche AG | 7934 |
8 |
Sumitomo Chemical Company, Limited | 9031 |
7 |
The Board of Trustees of the University of Illinois | 2685 |
7 |
Denali Therapeutics Inc. | 243 |
7 |
The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 163 |
7 |
The University of Queensland | 658 |
7 |
Boehringer Ingelheim International GmbH | 4697 |
6 |
VALO Health, Inc. | 172 |
6 |
Hoffmann-La Roche Inc. | 3404 |
5 |
Cornell University | 3292 |
5 |
Shionogi & Co., Ltd. | 860 |
5 |
Bristol-myers Squibb Company | 4879 |
4 |
Board of Regents, The University of Texas System | 5763 |
4 |
Astellas Pharma Inc. | 1088 |
4 |
Epizyme, Inc. | 370 |
4 |
Theravance, Inc. | 66 |
4 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2842 |
4 |
Vanderbilt University | 1894 |
4 |
Other owners | 165 |